Total Payments
$4.3M
2024 Payments
$432,082
Companies
122
Transactions
4,325
Medicare Patients
25,801
Medicare Billing
$8.1M
Payment Breakdown by Category
Other$2.6M (60.5%)
Consulting$1.1M (25.6%)
Travel$394,644 (9.1%)
Research$114,249 (2.6%)
Food & Beverage$87,985 (2.0%)
Education$881.21 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 814 | 54.0% |
| Consulting Fee | $1.1M | 288 | 25.6% |
| Travel and Lodging | $394,644 | 812 | 9.1% |
| Honoraria | $277,248 | 104 | 6.4% |
| Unspecified | $114,249 | 51 | 2.6% |
| Food and Beverage | $87,985 | 2,239 | 2.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,500 | 2 | 0.1% |
| Education | $881.21 | 14 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.0% |
Payments by Type
General
$4.2M
4,274 transactions
Research
$114,249
40 transactions
Ownership
$0
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $427,802 | 313 | $0 (2024) |
| Amgen Inc. | $342,148 | 309 | $0 (2024) |
| Heron Therapeutics, Inc. | $340,895 | 145 | $0 (2022) |
| ABBVIE INC. | $315,536 | 262 | $0 (2024) |
| Celgene Corporation | $220,604 | 174 | $0 (2024) |
| Daiichi Sankyo Inc. | $211,533 | 196 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $190,799 | 242 | $0 (2024) |
| Janssen Biotech, Inc. | $175,527 | 239 | $0 (2024) |
| Incyte Corporation | $173,292 | 169 | $0 (2024) |
| BeiGene USA, Inc. | $139,465 | 97 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $432,082 | 448 | Fennec Pharmaceuticals, Inc. ($102,511) |
| 2023 | $417,122 | 502 | BeiGene USA, Inc. ($56,520) |
| 2022 | $498,374 | 511 | E.R. Squibb & Sons, L.L.C. ($89,691) |
| 2021 | $393,668 | 456 | AstraZeneca Pharmaceuticals LP ($33,544) |
| 2020 | $452,017 | 406 | Celgene Corporation ($113,768) |
| 2019 | $722,531 | 674 | E.R. Squibb & Sons, L.L.C. ($162,864) |
| 2018 | $542,567 | 588 | AbbVie, Inc. ($96,509) |
| 2017 | $856,337 | 740 | Heron Therapeutics, Inc. ($268,443) |
All Payment Transactions
4,325 individual payment records from CMS Open Payments — Page 1 of 173
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: HORMONE THERAPY | ||||||
| 12/18/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $32.80 | General |
| Category: Oncology | ||||||
| 12/17/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | TALVEY (Biological) | Food and Beverage | In-kind items and services | $32.15 | General |
| Category: Oncology | ||||||
| 12/15/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Travel and Lodging | Cash or cash equivalent | $1,015.42 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 12/13/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $149.31 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 12/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $43.18 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,607.50 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $61.36 | General |
| 12/10/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $46.79 | General |
| Category: HEMATOLOGY | ||||||
| 12/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $111.87 | General |
| Category: Oncology | ||||||
| 12/08/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $46.12 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Food and Beverage | In-kind items and services | $385.96 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
| 12/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $4.27 | General |
| Category: Hematology | ||||||
| 12/04/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $17.20 | General |
| 12/03/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| 12/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $27.81 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/28/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Fennec Pharmaceuticals, Inc. | Pedmark (Drug) | Travel and Lodging | Cash or cash equivalent | $840.70 | General |
| Category: Cisplatin-induced Ototoxicity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | Takeda Development Center Americas, Inc. | $94,680 | 4 |
| A Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar DRLRI With MabThera in Subjects With Previously Untreated CD20-Positive LTB Follicular Lymphoma | Dr.Reddy's Laboratories,Inc. | $10,787 | 5 |
| A Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation SCT | Takeda Pharmaceuticals U.S.A., Inc. | $2,250 | 3 |
| A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma NDMM | Takeda Pharmaceuticals U.S.A., Inc. | $2,036 | 16 |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | ABBVIE INC. | $1,582 | 2 |
| An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia | GENZYME CORPORATION | $1,250 | 1 |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | AbbVie Inc. | $954.99 | 5 |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | AbbVie Inc. | $358.64 | 2 |
| TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | Takeda Pharmaceuticals U.S.A., Inc. | $351.54 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 6,238 | 230,314 | $10.1M | $2.5M |
| 2022 | 47 | 6,080 | 376,600 | $7.0M | $1.8M |
| 2021 | 51 | 6,666 | 289,463 | $5.8M | $1.9M |
| 2020 | 59 | 6,817 | 269,000 | $6.1M | $1.9M |
Total Patients
25,801
Total Services
1,165,377
Medicare Billing
$8.1M
Procedure Codes
200
All Medicare Procedures & Services
200 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 24,120 | $3.3M | $858,956 | 26.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 27 | 18,808 | $2.7M | $672,484 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 648 | 1,531 | $597,090 | $161,855 | 27.1% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 98 | 27,850 | $696,250 | $159,887 | 23.0% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 69 | 8,400 | $621,600 | $133,007 | 21.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 51 | 6,780 | $433,920 | $125,043 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 549 | 1,250 | $346,250 | $94,222 | 27.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 35 | 332 | $139,772 | $40,905 | 29.3% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 82 | 88,230 | $352,920 | $35,250 | 10.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 179 | 611 | $127,088 | $34,806 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 123 | 199 | $109,450 | $29,589 | 27.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 723 | 3,153 | $28,377 | $26,414 | 93.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 731 | 3,244 | $94,076 | $24,366 | 25.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 119 | 119 | $80,087 | $21,660 | 27.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 180 | 1,509 | $101,103 | $18,257 | 18.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 21 | 7,200 | $72,000 | $16,624 | 23.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 51 | 232 | $54,288 | $15,146 | 27.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 542 | 1,210 | $47,190 | $12,513 | 26.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 328 | 553 | $22,673 | $7,388 | 32.6% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 20 | 103 | $18,540 | $5,529 | 29.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 29 | 31 | $16,833 | $4,910 | 29.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 43 | 344 | $22,704 | $4,828 | 21.3% |
| 83550 | Iron binding capacity | Office | 2023 | 327 | 539 | $14,553 | $4,619 | 31.7% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 12 | 29,100 | $58,200 | $4,411 | 7.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 38 | 153 | $15,759 | $4,036 | 25.6% |
About Dr. Ralph Boccia, M.D
Dr. Ralph Boccia, M.D is a Medical Oncology healthcare provider based in Bethesda, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881663284.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ralph Boccia, M.D has received a total of $4.3M in payments from pharmaceutical and medical device companies, with $432,082 received in 2024. These payments were reported across 4,325 transactions from 122 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.3M).
As a Medicare-enrolled provider, Boccia has provided services to 25,801 Medicare beneficiaries, totaling 1,165,377 services with total Medicare billing of $8.1M. Data is available for 4 years (2020–2023), covering 200 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Bethesda, MD
- Active Since 03/16/2006
- Last Updated 01/03/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1881663284
Products in Payments
- SUSTOL (Drug) $314,480
- OPDIVO (Biological) $259,877
- Venclexta (Drug) $185,645
- Kyprolis (Biological) $167,672
- INJECTAFER (Drug) $166,994
- ERLEADA (Drug) $155,282
- BRUKINSA (Drug) $139,340
- LIBTAYO (Biological) $138,944
- JAKAFI (Drug) $101,930
- DOPTELET (Drug) $99,653
- Nplate (Biological) $99,446
- Tavalisse (Drug) $95,077
- Pedmark (Drug) $86,511
- SARCLISA (Biological) $84,367
- MONOFERRIC (Drug) $83,605
- INREBIC (Drug) $82,951
- NINLARO (Drug) $81,506
- Doptelet (Drug) $77,370
- XPOVIO (Drug) $71,108
- COSELA (Drug) $69,433
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Bethesda
Adrian Senderowicz, Md, MD
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Dr. Richard Piekarz, Md, MD
Medical Oncology — Payments: $167,988
Medical Oncology $167,988
Dr. Lee Helman, Md, MD
Medical Oncology — Payments: $51,392
Medical Oncology $51,392
Victor Priego, M.d, M.D
Medical Oncology — Payments: $48,721
Medical Oncology $48,721
Dr. Christopher Klebanoff, M.d, M.D
Medical Oncology — Payments: $28,531
Medical Oncology $28,531
Christian Hinrichs, M.d, M.D
Medical Oncology — Payments: $17,331
Medical Oncology $17,331